Navigation Links
Champions Biotechnology Awarded $1.46 million in Grants
Date:11/3/2010

urities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2010 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.

CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE: www.championsbiotechnology.comContact: James CarbonaraThe Investor Relations Group, Inc. 212-825-3210For Champions Biotechnology, Inc.
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
4. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
5. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  CytRx Corporation (CYTR), a biopharmaceutical ... reported financial results for the three months ended ... recent accomplishments and upcoming milestones for its clinical ... in the early months of 2015, including the ... of aldoxorubicin in patients with soft tissue sarcoma, ...
(Date:5/1/2015)... , May 1, 2015  Boston Scientific Corporation ... its continued business momentum and long-term growth strategies at ... New York City . President and Chief ... unique opportunities the company has to bring forward meaningful ... growing markets and deliver shareholder value. ...
(Date:5/1/2015)... YORK , May 1, 2015  Shares of ... 70% of their value yesterday following the results of ... glaucoma therapy, Rhopressa.  Despite the trial failing to meet ... that positive results may come from future studies. ... brief company overview, current pipeline, financial review, analyst summary, ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... 05, 2007 /PRNewswire/ -- Results from,the primary ... study showed that 77 percent of treatment-experienced ... tablets with,100 mg ritonavir (PREZISTA/r) twice daily, ... (ARV) agents, reached a,plasma viral load of ...
... Cobalis Corp.,(OTCBB:CLSC), a pharmaceutical development company specializing ... two Phase III clinical trials for its ... severe,seasonal allergic rhinitis, commonly known as hay ... in both placebo and,PreHistin-treated patient groups, thereby ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 2Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 3Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 4Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 5
(Date:5/3/2015)... (PRWEB) May 03, 2015 “ BolehVPN ” ... Report, which features the latest and coolest technology products available ... for NewsWatch, conducted the review and shared with viewers how ... everyone does these days is on computers and even more ... families and meet people all over the world. In terms ...
(Date:5/3/2015)... It is not too late to register to take part in ... Anne Been in Arnold, Missouri on May 9, 2015. Family ... her loving memory. It has benefited the renowned Brain Aneurysm Foundation ... Lissa suffered a brain aneurysm . After two operations and ... is designed to serve as a remembrance of her and to ...
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... 2015 We are pleased to announce ... Center as one of the Top Workplaces of 2015. ... addiction treatment field for their ethics and standards of ... to continue their educational efforts. The Delray Recovery Center ... forgetting their purpose – to help individuals heal from ...
(Date:5/2/2015)... May 02, 2015 As a ... issues of the face, neck and décolleté, radiofrequency ... with real potential for the success of vulvovaginal ... ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s Health Clinical ... ACGE, concluded that ThermiGyn’s temperature controlled radio frequency, ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... that enables a surgeon to perform laparoscopic gall bladder and ... computer and video monitor. The surgeon can use hand grips ... arms that can perform the surgery using a variety of ... by Intuitive Surgical, Inc., of Mountain View, Calif., is the ...
... Lung, and Blood Institute (NHLBI) and the National High ... recommendations to treat Hypertension.,Control of systolic blood pressure is ... is a crucial message for health care providers, patients, ... lowering systolic blood pressure to less than 140 mm ...
... from June issue of the American Journal of Epidemiology ... rates than taller people from most causes except cancer. ... women undertaken by Dr.Pekka Jousilahti and his colleagues from ... was found that there was an association between adult ...
... high levels of cholesterol but low levels that are making ... Cholesterol maybe linked to depression and violent behavior. A new ... up to seven times more likely to report symptoms of ... Center in Durham, N.C. Said, "I think that ...
... ,Death Rates Higher for Those Without This Symptom. As many ... or during a heart attack, a study published in The ... diabetics and others who belong to groups likely to have ... such pains. ,The report examined symptoms in more than 400,000 ...
... of the most common cancers in women. If it is ... The Pap smear is the standard screening method for the ... cervical cells. ,Two strains of the human papilloma virus (HPV) ... but not all women who test positive, develop the disease. ...
Cached Medicine News:
... The NIDEK YC-1800 is an ... laser delivery and output technologies, improved ... offset and compact design with versatility ... YC-1800 replaces the YC-1600 and adds ...
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... • V-shaped bottom allows easy ... lips facilitate pour-out ,• Nesting ring ... Solution Basin designed for 4, 8, and ... V-shaped bottom permits withdrawal of practically all ...
Medicine Products: